导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.70% | 1833/4773 |
| 近一周 | -2.94% | 3413/5462 |
| 近一月 | -3.07% | 1541/5421 |
| 近一季 | -8.80% | 2962/5209 |
| 近半年 | -6.37% | 3071/4920 |
| 近一年 | 5.04% | 1641/4366 |
| 近两年 | 83.35% | 760/2954 |
| 近三年 | 40.50% | 710/2253 |
| 成立以来 | 24.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.20% 1342/4961 |
12.66% 2140/5312 |
- - |
- - |
| 2025 | 31.47% 1236/4813 |
5.75% 739/3635 |
4.46% 755/4076 |
16.66% 2619/4524 |
2.02% 1111/4813 |
| 2024 | 5.88% 1808/3463 |
-6.52% 2060/2808 |
-8.94% 2307/3014 |
14.09% 2047/3129 |
9.01% 355/3463 |
| 2023 | -6.54% 857/2656 |
6.40% 692/2280 |
-5.64% 1510/2385 |
-5.26% 1300/2515 |
-1.74% 365/2655 |
| 2022 | -23.77% 1168/2207 |
-17.46% 1210/1919 |
7.46% 472/2016 |
-14.82% 1157/2113 |
0.90% 1432/2208 |
| 2021 | 10.57% 428/1822 |
-4.65% 880/1255 |
10.73% 440/1330 |
-1.89% 548/1466 |
6.74% 206/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发国证2000ETF联接C VS. 长安沪深300非周期A(740101) |